Interception

A significant family history or an identified genetic mutation (BRCA1/2, Lynch, Li-Fraumeni, etc.) can significantly increase the risk of developing certain cancers. An oncogenetic consultation helps determine this risk and tailor screening recommendations.

Certain lesions detected during routine examinations (colorectal polyps, cervical lesions, atypical breast lesions, etc.) are indicators that warrant enhanced and personalized follow-up.

Tobacco is the leading preventable cause of cancer. Other occupational or environmental exposures (asbestos, radon, arsenic, chromium, etc.) can also increase your risk. A personalized assessment can help evaluate your level of exposure.

Quitting smoking, staying physically active, eating a balanced diet, and limiting alcohol consumption are all ways to reduce your risk of cancer. The Interception program includes support for nutrition and physical activity.

For women with a BRCA1/2 or PALB2 mutation, or other hereditary predispositions that increase the risk of breast cancer. Enhanced follow-up: annual MRI, tailored mammography, and oncogenetics.

For women at increased risk of breast cancer without an identified mutation: high breast density, a history of atypical lesions, or a significant family history.

For heavy smokers aged 50 to 74 (>20 pack-years), whether current smokers or those who quit less than 10 years ago. Annual low-dose chest CT screening + personalized smoking cessation plan.

For people with Lynch syndrome (MLH1, MSH2, MSH6, or PMS2 mutations). Monthly dedicated day: nutrition and exercise workshops, consultation with a gastrointestinal oncologist, and a scheduled colonoscopy.

For individuals with a first-degree relative who has colorectal cancer, a history of polyps, or other non-genetic high-risk factors. New care pathway launching in late 2025.

For individuals with a TP53 mutation (Li-Fraumeni syndrome) who are at increased risk for multiple cancers. Intensive, personalized multi-organ monitoring.

For individuals with rare predisposing genetic abnormalities (excluding TP53/BRCA/Lynch): CDH1, STK11, SDHA/B/C/D, attenuated APC, etc. Multidisciplinary care.

For adults who have been cured of pediatric cancer and are at increased risk of developing secondary cancers due to the treatments they received (radiation therapy, anthracycline chemotherapy, etc.).

For men with a genetic mutation that increases the risk of prostate cancer (BRCA2, HOXB13, etc.). Monitoring via enhanced PSA testing and biopsies tailored to the individual’s profile.

For individuals with clonal hematopoiesis of undetermined potential (CHIP), a marker of risk for the development of a malignant blood disorder. Monitoring and prevention program.

For people at increased risk of pancreatic cancer: those with BRCA2 or CDKN2A mutations, or a family history of the disease. Monitoring via MRI and endoscopic ultrasound.

Physicians—whether in private practice or at hospitals—can refer their patients to the Interception program after identifying situations in which their patients have an increased risk of cancer.

See the different patient profiles involved: Interception Pathways [notes: dedicated page for each pathway?]

To better identify these risk situations, doctors can use the free online software developed by Gustave Roussy, available upon request from the Interception team:

Contact the Interception team (response within 48 business hours)

If you are a patient, please discuss your care with your referring physician, who can contact us if he or she deems it necessary.

Your doctor can schedule an appointment directly:

Via Doctolib—search for “Interception Gustave Roussy”

By phone: 01 42 11 23 75 (Monday–Friday, 8:30 a.m.–5:00 p.m.)

By email: interception@gustaveroussy.fr

If you are enrolled in the Interception program and have symptoms that may indicate cancer, or if you have been diagnosed with cancer, please contact our teams to arrange for urgent care:

Phone: 01 42 11 23 75

Email: interception@gustaveroussy.fr

Our teams will respond within 48 business hours.

We ask Interception participants to provide us with a brief update each year. The cohort formed in this way helps us improve our understanding of individual risks and assess the impact of the proposed interventions.

If new interventions become available (such as specialized screening or innovative prevention methods), participants and their doctors may be contacted.